IMPROVING DEMENTIA ECONOMICS THROUGH EARLIER COST-EFECTIVE ASSESSMENT
Author(s)
Carroll K1, McCollum J1, Charvat M2
1Savonix Inc., San Francisco, CA, USA, 2Savonix, San Francisco, CA, USA
Presentation Documents
Dementia is quickly becoming a universal financial catastrophe. Approximately 50 million people have dementia, with 10 million new diagnoses every year and a worldwide estimate of 82 million in 2030. This increase is predicted to have dire global economic costs, and the economic burden is expected to grow to 604 billion dollars (Wimo). These predictions indicate the substantial universal need for earlier detection geared towards postponing the onset of dementia. Early identification could either delay the onset of dementia or slow its progression by one or two years, and the global burden of this disease would be significantly reduced with potentially 20% fewer cases of Alzheimer’s disease occurring in 2050. Cost benefit analyses show that early diagnosis and treatment is more monetarily efficient than contemporary practices. Specifically, over a ten-year period, Saito predicted a cost reduction of 9.8% and Banerjee reported savings of £950 million. Of course, early identification and diagnosis also allow for earlier social and economic planning. Postponing the onset of dementia can be achieved by both social/lifestyle and medication interventions. Several studies are examining the impact of lifestyles factors (i.e. FINGERS study) designed to educate and promote healthier lifestyles. Recently, digital therapeutics, or cognitive games, have been proposed as a way of maintaining and even improving cognitive functioning. Research suggests that the early use of pharmacological interventions can delay institutionalization; however, medication interventions are most effective earlier in the course of the disease. Unfortunately, present-day screening program costs are relatively high and inefficient. However, inexpensive, readily accessible, and accurate digital mobile technologies are now available and can expedite low-cost baseline cognitive screening to promote faster and more accurate diagnoses in populations who would otherwise lack access to cognitive healthcare interventions. These screenings could potentially reverse and/or retard the advancement of dementia, likely leading to significant economic returns.
Conference/Value in Health Info
2019-05, ISPOR 2019, New Orleans, LA, USA
Value in Health, Volume 22, Issue S1 (2019 May)
Code
PIH14
Topic
Medical Technologies
Topic Subcategory
Diagnostics & Imaging, Digital Health
Disease
Geriatrics